Teva’s Olanzapine Injectable for Schizophrenia Receives FDA Acceptance OR FDA Accepts Teva’s NDA for Extended-Release Olanzapine Injection OR Teva Submits New Schizophrenia Treatment – FDA Application Accepted
- Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for a novel formulation of olanzapine, an antipsychotic medication used in the treatment of schizophrenia in...
- Schizophrenia is a chronic mental disorder affecting approximately 1% of the global population, impacting a person’s ability to think, feel, and behave clearly.
- Currently available long-acting injectable (LAI) formulations of olanzapine require administration in a certified healthcare facility, followed by a mandatory three-hour post-injection monitoring period.
The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for a novel formulation of olanzapine, an antipsychotic medication used in the treatment of schizophrenia in adults. The application, submitted by Teva Pharmaceuticals, concerns an extended-release injectable suspension – designated TEV-‘749 – designed for once-monthly administration. , Teva announced the FDA’s acceptance, marking a significant step toward potentially addressing a critical need for more convenient and adherence-friendly treatment options for individuals living with schizophrenia.
Addressing the Challenges of Schizophrenia Treatment
Schizophrenia is a chronic mental disorder affecting approximately 1% of the global population, impacting a person’s ability to think, feel, and behave clearly. Symptoms can include delusions, hallucinations, disorganized speech, and impaired cognitive function. Effective management often relies on consistent medication adherence, a challenge for many patients due to the nature of the illness and the potential for side effects.
Currently available long-acting injectable (LAI) formulations of olanzapine require administration in a certified healthcare facility, followed by a mandatory three-hour post-injection monitoring period. This requirement can present logistical hurdles for patients and healthcare providers, potentially impacting treatment adherence. TEV-‘749 aims to overcome these obstacles by offering a once-monthly subcutaneous injection that, according to data from a Phase 3 clinical trial, does not necessitate this extended monitoring period.
TEV-‘749: A New Approach to Olanzapine Delivery
The development of TEV-‘749 leverages a proprietary copolymer technology from Medincell, Teva’s partner in this endeavor. This technology is designed to provide a controlled, steady, and sustained release of olanzapine, potentially improving real-world treatment adherence and helping patients maintain long-term stability. The application was based on data from a late-stage trial where TEV-‘749, administered as a once-monthly subcutaneous injection, demonstrated an efficacy and safety profile consistent with existing olanzapine formulations.
“Treatment adherence remains a major challenge and unmet need for people living with schizophrenia,” said Eric Hughes, Chief Medical Officer at Teva. This statement underscores the importance of developing formulations that simplify the treatment process and reduce the burden on patients.
Clinical Trial Results and Safety Profile
The Phase 3 SOLARIS trial, which supported the NDA submission, demonstrated that TEV-‘749 exhibited a comparable efficacy and safety profile to currently available olanzapine formulations. Importantly, the trial showed no evidence suggesting the need for post-injection monitoring, a key differentiator from existing LAI options. This finding could significantly improve the patient experience and reduce the demands on healthcare resources.
Teva’s Broader Strategy and Recent Legal Victory
This NDA acceptance aligns with Teva’s “Pivot to Growth” strategy, which emphasizes the development of innovative treatments in complex neurological conditions. The company is focused on expanding its portfolio of differentiated long-acting injectable (LAI) medications.
In a separate development earlier this week, Teva secured a legal victory in a patent dispute involving Corcept Therapeutics’ Korlym tablets. The United States Court of Appeals for the Federal Circuit ruled in favor of Teva, a positive outcome for the company’s generics business.
Market Reaction and Future Outlook
As of the time of reporting, shares of Teva (NYSE and TASE: TEVA) experienced only marginal fluctuations following the announcement. However, the potential approval of TEV-‘749 could have a more substantial impact on the company’s long-term growth prospects, particularly within the schizophrenia treatment market.
The FDA’s acceptance of the NDA initiates a review process, the duration of which is not specified. If approved, TEV-‘749 could offer a valuable new option for individuals with schizophrenia, potentially improving treatment outcomes and quality of life by addressing the challenges associated with medication adherence. The development represents a step forward in providing more patient-centric and convenient treatment approaches for this complex and debilitating condition.